Showing results (231-240 of 241) with videos related to

Sort By:
Pageof 25
The Lancet. Infectious Diseases|September 16, 2021
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trialDavid Ishola, Daniela Manno, Muhammed O Afolabi, et al.
The Lancet. Infectious Diseases|October 23, 2022
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trialDaniela Manno, Agnes Bangura, Frank Baiden, et al.
The New England Journal of Medicine|December 14, 2022
Randomized Trial of Vaccines for Zaire Ebola Virus Disease, Mark Kieh, Laura Richert, et al.
Lancet (London, England)|June 11, 2013
Mortality risk in preterm and small-for-gestational-age infants in low-income and middle-income countries: a pooled country analysisJoanne Katz, Anne Cc Lee, Naoko Kozuki, et al.
Vaccines|August 29, 2024
Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants during an Outbreak in the Democratic Republic of the CongoHugo Kavunga-Membo, Deborah Watson-Jones, Kambale Kasonia, et al.
Medrxiv : the Preprint Server for Health Sciences|June 22, 2026
Five-year immunogenicity and safety follow-up of the PREVAC randomized Trial of Vaccines for Zaire Ebola Virus DiseaseAbdoul Habib Beavogui, Seydou Doumbia, Mark Kieh, et al.
American Journal of Medical Genetics. Part A|February 8, 2023
A mutational hotspot in AMOTL1 defines a new syndrome of orofacial clefting, cardiac anomalies, and tall statureAlanna Strong, Soumya Rao, Sandra von Hardenberg, et al.
Plos One|June 12, 2026
Comparison of self-collected vaginal swabs and first-void urine for detection of human papillomavirus in sexually active girls and women in three South Asian countriesNigus Telele, Nishan Katuwal, Furqan Kabir, et al.
The Lancet. Global Health|October 20, 2023
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra LeoneEdward Man-Lik Choi, Boris Lacarra, Muhammed O Afolabi, et al.
BMJ (Clinical Research Ed.)|August 19, 2017
Estimates of burden and consequences of infants born small for gestational age in low and middle income countries with INTERGROWTH-21st standard: analysis of CHERG datasetsAnne Cc Lee, Naoko Kozuki, Simon Cousens, et al.
Pageof 25